Arrowstreet Capital
CRBP icon

Arrowstreet Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Arrowstreet Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,893
Closed -$184K – 2283
2020
Q4 		$184K Buy
+4,893
New +$183K ﹤0.01% 2191

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arrowstreet Capital's CRBP Position: Q1 2021 in Review

Arrowstreet Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2021, closing a stake of 4,893 shares — an estimated $184K sold.

Arrowstreet Capital first reported a position in CRBP in Q4 2020 and held it in 1 quarter. The position peaked at $184K in Q4 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2021.

  • Arrowstreet Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 4,893 Corbus Pharmaceuticals shares in Q1 2021, an estimated $184K.
  • Arrowstreet Capital first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Corbus Pharmaceuticals position peaked at $184K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.